133 related articles for article (PubMed ID: 12750153)
1. Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions.
Huntly BJ; Guilhot F; Reid AG; Vassiliou G; Hennig E; Franke C; Byrne J; Brizard A; Niederwieser D; Freeman-Edward J; Cuthbert G; Bown N; Clark RE; Nacheva EP; Green AR; Deininger MW
Blood; 2003 Sep; 102(6):2205-12. PubMed ID: 12750153
[TBL] [Abstract][Full Text] [Related]
2. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia.
Quintas-Cardama A; Kantarjian H; Talpaz M; O'Brien S; Garcia-Manero G; Verstovsek S; Rios MB; Hayes K; Glassman A; Bekele BN; Zhou X; Cortes J
Blood; 2005 Mar; 105(6):2281-6. PubMed ID: 15572595
[TBL] [Abstract][Full Text] [Related]
3. High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study.
Petzer AL; Wolf D; Fong D; Lion T; Dyagil I; Masliak Z; Bogdanovic A; Griskevicius L; Lejniece S; Goranov S; Gercheva L; Stojanovic A; Peytchev D; Tzvetkov N; Griniute R; Oucheva R; Ulmer H; Kwakkelstein M; Rancati F; Gastl G
Haematologica; 2010 Jun; 95(6):908-13. PubMed ID: 20145273
[TBL] [Abstract][Full Text] [Related]
4. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Cortes J; Talpaz M; O'Brien S; Giles F; Beth Rios M; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Kantarjian H
Cancer; 2003 Sep; 98(6):1105-13. PubMed ID: 12973833
[TBL] [Abstract][Full Text] [Related]
5. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.
Talpaz M; Silver RT; Druker BJ; Goldman JM; Gambacorti-Passerini C; Guilhot F; Schiffer CA; Fischer T; Deininger MW; Lennard AL; Hochhaus A; Ottmann OG; Gratwohl A; Baccarani M; Stone R; Tura S; Mahon FX; Fernandes-Reese S; Gathmann I; Capdeville R; Kantarjian HM; Sawyers CL
Blood; 2002 Mar; 99(6):1928-37. PubMed ID: 11877262
[TBL] [Abstract][Full Text] [Related]
6. Molecular cytogenetic study of derivative chromosome 9 deletion in chronic myeloid leukemia patients.
Bennour A; Ouahchi I; Ben Youssef Y; Zaier M; Laatiri MA; Harrabi I; Meddeb B; Elloumi M; Khelif A; Saad A; Sennana H
Med Oncol; 2012 Jun; 29(2):1151-60. PubMed ID: 21461967
[TBL] [Abstract][Full Text] [Related]
7. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
Kim DH; Popradi G; Sriharsha L; Kamel-Reid S; Chang H; Messner HA; Lipton JH
Cancer; 2008 Aug; 113(4):772-81. PubMed ID: 18543309
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
Kantarjian H; O'Brien S; Cortes J; Shan J; Giles F; Garcia-Manero G; Verstovsek S; Faderl S; Rios MB; Talpaz M
Cancer; 2003 Oct; 98(7):1430-7. PubMed ID: 14508830
[TBL] [Abstract][Full Text] [Related]
9. [Tyrosine kinase inhibitors for the treatment of CML].
Heim D
Ther Umsch; 2006 Apr; 63(4):249-54. PubMed ID: 16689455
[TBL] [Abstract][Full Text] [Related]
10. Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls.
Kantarjian H; O'Brien S; Cortes J; Giles F; Shan J; Rios MB; Faderl S; Verstovsek S; Garcia-Manero G; Wierda W; Kornblau S; Ferrajoli A; Keating M; Talpaz M
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):68-75. PubMed ID: 14734453
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy.
Cortes JE; Talpaz M; Giles F; O'Brien S; Rios MB; Shan J; Garcia-Manero G; Faderl S; Thomas DA; Wierda W; Ferrajoli A; Jeha S; Kantarjian HM
Blood; 2003 May; 101(10):3794-800. PubMed ID: 12560227
[TBL] [Abstract][Full Text] [Related]
12. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.
Kantarjian H; Talpaz M; O'Brien S; Garcia-Manero G; Verstovsek S; Giles F; Rios MB; Shan J; Letvak L; Thomas D; Faderl S; Ferrajoli A; Cortes J
Blood; 2004 Apr; 103(8):2873-8. PubMed ID: 15070658
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic therapy with hydralazine and magnesium valproate reverses imatinib resistance in patients with chronic myeloid leukemia.
Cervera E; Candelaria M; López-Navarro O; Labardini J; Gonzalez-Fierro A; Taja-Chayeb L; Cortes J; Gordillo-Bastidas D; Dueñas-González A
Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):207-12. PubMed ID: 22420986
[TBL] [Abstract][Full Text] [Related]
14. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.
Jabbour E; Kantarjian HM; Jones D; Shan J; O'Brien S; Reddy N; Wierda WG; Faderl S; Garcia-Manero G; Verstovsek S; Rios MB; Cortes J
Blood; 2009 Mar; 113(10):2154-60. PubMed ID: 19060245
[TBL] [Abstract][Full Text] [Related]
15. Initial treatment for patients with CML.
Goldman JM
Hematology Am Soc Hematol Educ Program; 2009; ():453-60. PubMed ID: 20008231
[TBL] [Abstract][Full Text] [Related]
16. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Rios MB; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Verstovsek S; Wierda W; Keating M; Talpaz M
Cancer; 2003 Dec; 98(12):2636-42. PubMed ID: 14669283
[TBL] [Abstract][Full Text] [Related]
17. The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment.
Zonder JA; Pemberton P; Brandt H; Mohamed AN; Schiffer CA
Clin Cancer Res; 2003 Jun; 9(6):2092-7. PubMed ID: 12796373
[TBL] [Abstract][Full Text] [Related]
18. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
[TBL] [Abstract][Full Text] [Related]
19. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
[TBL] [Abstract][Full Text] [Related]
20. In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells.
Scappini B; Onida F; Kantarjian HM; Dong L; Verstovsek S; Keating MJ; Beran M
Cancer; 2002 May; 94(10):2653-62. PubMed ID: 12173333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]